Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial

Autor: Hsia, Judith, Kavanagh, Sarah T, Hopley, Charles W, Baumgartner, Iris, Berger, Jeffrey S, Fowkes, Gerry R, Jones, W Schuyler, Mahaffey, Kenneth W, Norgren, Lars, Patel, Manesh R, Rockhold, Frank, Blomster, Juuso, Katona, Brian G, Hiatt, William R, Bonaca, Marc P

Patients with chronic kidney disease may develop new or more severe anemia when treated with antiplatelet agents due to blood loss in conjunction with impaired erythropoiesis. Because anemia independently predicts limb amputation and mortality among

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce475c3097c60508e0633993c475f90d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y 12 inhibitors: Insights from the EUCLID trial.

Autor: Hsia J; CPC Clinical Research, Aurora, CO, USA.; Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA., Kavanagh ST; CPC Clinical Research, Aurora, CO, USA., Hopley CW; Department of Medicine, Geisel School of Medicine at Dartmouth, Dartmouth Hitchcock Medical Center, Hanover, NH, USA., Baumgartner I; Department of Angiology, Inselspital, Bern, Switzerland., Berger JS; Departments of Medicine and Surgery, New York University School of Medicine, New York, NY, USA., Fowkes GR; Centre for Population Health Sciences, University of Edinburgh, Edinburgh, Scotland., Jones WS; Duke Clinical Research Institute, Duke University, Durham, NC, USA., Mahaffey KW; Stanford University School of Medicine, Palo Alto, CA, USA., Norgren L; Faculty of Medicine and Health, Örebro University Hospital, Örebro, Sweden., Patel MR; Duke Clinical Research Institute, Duke University, Durham, NC, USA., Rockhold F; Duke Clinical Research Institute, Duke University, Durham, NC, USA., Blomster J; AstraZeneca LP, Gothenburg, Sweden; Gaithersburg, MD, USA., Katona BG; AstraZeneca LP, Gothenburg, Sweden; Gaithersburg, MD, USA., Hiatt WR; CPC Clinical Research, Aurora, CO, USA.; Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA., Bonaca MP; CPC Clinical Research, Aurora, CO, USA.; Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.

Publikováno v: Vascular medicine (London, England) [Vasc Med] 2021 Dec; Vol. 26 (6), pp. 608-612. Date of Electronic Publication: 2021 Jun 03.